米格鲁斯塔通过向UGCG来改善因异二醇诱导的心脏纤维化
Jing Liu1, Wenqi Li1, Ran Jiao1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300353, China.
Molecular medicine (Cambridge, Mass.)
|February 11, 2025
概括
米格鲁斯塔 (Mig) 降低了由β-上腺素受体 (β-AR) 过度激活引起的心脏纤维化和功能障碍. 它通过抑制关键信号通路和向UDP-葡萄糖胺糖酶转移酶 (UGCG) 来起作用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 心脏纤维化是导致心力衰竭的主要原因,通常与β-上腺素受体 (β-AR) 过度激活有关.
- 在各种疾病中,Miglustat (Mig) 已表现出抗纤维性质.
- 通过Mig可能抵消β-AR过度激活诱导的心脏纤维化的特定机制仍然在很大程度上未被探索.
研究的目的:
- 为了研究米格卢斯塔特 (Mig) 在改善因β-上腺素受体 (β-AR) 过度激活引起的心脏纤维化方面的疗效.
- 阐明 Mig 对心脏纤维化产生保护作用的潜在分子机制.
主要方法:
- 在小鼠中使用异二醇 (ISO) 诱导心脏纤维化,随后用米格卢斯塔特 (Mig) 治疗.
- 在体外研究中使用了用ISO刺激并用Miglustat治疗的初级心脏纤维细胞.
- 用分子和成像技术评估心脏纤维化,功能障碍和纤维细胞激活,包括基因表达,西部斑点和回声心脏学.
- 通过GEO数据分析和基因淘汰实验,探索了UDP-葡萄糖胺糖转移酶 (UGCG) 的作用.
主要成果:
- 在体内,Miglustat治疗显著缓解了异二醇诱导的心脏功能障碍和纤维化.
- 米格鲁斯塔特减弱了心脏纤维细胞的激活,以应对异二醇刺激.
- 该药物逆转了异二醇诱导的关键信号通路的激活:ERK,STAT3,Akt和GSK3β.
- 米格尔斯塔特通过向心脏纤维细胞中的UDP-葡萄糖胺糖基转移酶 (UGCG) 显示出保护作用.
结论:
- 米格鲁斯塔特有效地改善了与β-上腺素受体 (β-AR) 过度激活相关的心脏纤维化和功能障碍.
- 米格鲁斯塔特的治疗效益包括抑制ERK,STAT3,Akt和GSK3β信号通路.
- UDP-葡萄糖胺糖基转移酶 (UGCG) 成为治疗心脏纤维化的潜在治疗点.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
374
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
374
01:26Heart Failure Drugs: Inotropic Agents
504
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
504
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
145
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
145